BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Drug Discovery

Vertex's Breakthrough VX-548: Transforming Pain Management with Rapid Relief and Safety, A New Era in Acute Pain Solutions

Treatment with VX-548 led to statistically significant improvement in pain compared to placebo as well as a clinically meaningful reduction in pain from ...

January 31, 2024 | News

Fresenius Kabi Launches Posaconazole Injection for Fungal Infection Prevention/Treatment

Fresenius Kabi announced it has introduced Posaconazole Injection, a generic substitute for Noxafil®, for use in treating or preventing serious fungal ...

January 30, 2024 | News

Peijia Medical Completes Enrollment for TaurusTrio™ Aortic Regurgitation Trial

The multi-center trial utilized the TaurusTrioTM TAVR system to treat pure AR in 116 patients across 13 hospitals within China and is design...

January 30, 2024 | News

Ractigen Therapeutics Partners with Utrecht Medical Center for saRNA Innovation in Neurodevelopmental Disorders

Professor Bobby Koeleman, Group Leader at the Department of Genetics within the Center for Molecular Medicine at Utrecht University, will le...

January 30, 2024 | News

Travere Therapeutics Licenses Sparsentan to Renalys Pharma for Japan, South Korea, Taiwan, and Southeast Asia

Travere Therapeutics,announced that it has entered into an exclusive licensing agreement with Renalys Pharma, Inc., to bring sparsentan, a dual endothelin ...

January 29, 2024 | News

Eisai Seeks Approval in Japan for Ultrahigh-Dose Mecobalamin in ALS

This application is based on the results of JETALS (The Japan Early-Stage Trial of Ultrahigh-Dose Methylcobalamin for ALS), a Phase III trial to evaluate e...

January 29, 2024 | News

Ascletis Initiates Phase III Trial of ASC40 (Denifanstat) for Acne Treatment with First Patient Dosed

This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and e...

January 25, 2024 | News

Onward Therapeutics Initiates Phase 1 Trial for Bispecific Antibody OT-A201 Targeting Dual Immune Checkpoints

The study aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumoral activity of OT-A201. The study is a Eur...

January 25, 2024 | News

EMA grants Orphan Drug Designation to GC Biopharma's Sanfilippo Syndrome (Type A) Treatment

GC1130A has previously achieved notable milestones by securing both Rare Pediatric Disease designation (RPDD) and Orphan Drug Designation (ODD) from the U....

January 24, 2024 | News

Australia's Island Pharma Advances ISLA-101 Study: Third Cohort Successfully Dosed

This achievement follows the recent confirmation from the Data Safety Review Committee that ISLA-101 has been deemed safe and well-tolerated in the 16 subj...

January 23, 2024 | News

AIM ImmunoTech Initiates Phase 1b/2 Trial for Ampligen® and AstraZeneca's Imfinzi® in Late-Stage Pancreatic Cancer

AIM ImmunoTech Inc. announced that the first subject has been enrolled at Erasmus Medical Center in a Phase 1b/2 clinical trial combining AIM&rs...

January 23, 2024 | News

Vaxart Gets $9.27M BARDA Award for Phase 2b COVID-19 Oral Pill Study

“We are very honored to receive this BARDA award, which will support the innovative approach of our oral pill vaccine platform,” said Dr. Micha...

January 22, 2024 | News

AstraZeneca's IMFINZI Combo Shows Significantly Improved Survival in Liver Cancer

Positive results from the EMERALD-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with TACE and bevacizumab demo...

January 22, 2024 | News

InnoCare Prescribes Tafasitamab Combo for Diffuse Large B-Cell Lymphoma in Greater Bay Area's Early Access Program

The early access program of the Greater Bay Area allows designated medical institutions in the area to access drugs and medical devices that have been appr...

January 22, 2024 | News

Stay Connected